State pharmaceutical firm Indofarma (INAF) reported a 36.6% decline in sales, to Rp364 billion in the first half (H1) of 2023. It suffered net loss of Rp120.3 billion in said period, expanded from Rp90.7 billion loss in H1 of 2022. Full year target, accordingly, is increasingly out of reach. To subscribe please click here
